文献速递治疗药物监测与药物基因组学抗栓抗凝管理特殊人群用药

华法林药物基因组学在不同种族人群中的考量

Warfarin Pharmacogenomics in Diverse Populations.
PubMed 文献 · Pharmacotherapy · 2017-09-06

综述指出基因型指导的华法林剂量算法可优化剂量并可能减少不良事件,但现有证据主要来自欧洲血统人群。非裔美国人和拉丁裔等多样人群华法林剂量需求变异更大且不良事件风险更高,需考虑种族/民族特异性或混合血统算法以成功临床实施。

要点

  • 基因型指导华法林剂量算法在多样人群中证据有限,多数研究基于欧洲血统人群。
  • 非裔美国人和拉丁裔剂量需求变异更大且华法林相关不良事件风险更高。
  • 不包含跨种族重要变异的算法难以惠及多样人群,需开发种族特异或混合血统算法。

核心结论

  • 基因型指导华法林剂量算法是优化剂量并可能减少不良事件的合理方法。
  • 现有证据多来自欧洲血统人群,多样人群可能受益但证据不足。
  • 需考虑种族/民族和额外证据以成功临床实施华法林药物基因组学。

研究设计与样本

  • 本文为综述,检索范围未明确报告。

主要发现

  • 非裔美国人和拉丁裔华法林剂量需求变异更大且不良事件风险高于欧洲血统个体。
  • 多数多样人群证据评估的是欧洲血统常见变异,尽管变异频率随种族/民族不同。
  • 不包含跨种族重要变异的算法不太可能惠及多样人群。

临床怎么用

  • 解读基因型指导华法林剂量文献时应考虑种族/民族差异。
  • 临床实施华法林药物基因组学需关注种族/民族并积累跨种族算法证据。

局限性

  • 前瞻性随机试验数据主要来自欧洲血统人群,多样人群证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genotype-guided warfarin dosing algorithms are a rational approach to optimize warfarin dosing and potentially reduce adverse drug events. Diverse populations, such as African Americans and Latinos, have greater variability in warfarin dose requirements and are at greater risk for experiencing warfarin-related adverse events compared with individuals of European ancestry. Although these data suggest that patients of diverse populations may benefit from improved warfarin dose estimation, the vast majority of literature on genotype-guided warfarin dosing, including data from prospective randomized trials, is in populations of European ancestry. Despite differing frequencies of variants by race/ethnicity, most evidence in diverse populations evaluates variants that are most common in populations of European ancestry. Algorithms that do not include variants important across race/ethnic groups are unlikely to benefit diverse populations. In some race/ethnic groups, development of race-specific or admixture-based algorithms may facilitate improved genotype-guided warfarin dosing algorithms above and beyond that seen in individuals of European ancestry. These observations should be considered in the interpretation of literature evaluating the clinical utility of genotype-guided warfarin dosing. Careful consideration of race/ethnicity and additional evidence focused on improving warfarin dosing algorithms across race/ethnic groups will be necessary for successful clinical implementation of warfarin pharmacogenomics. The evidence for warfarin pharmacogenomics has a broad significance for pharmacogenomic testing, emphasizing the consideration of race/ethnicity in discovery of gene-drug pairs and development of clinical recommendations for pharmacogenetic testing.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Kaye JB, Schultz LE, Steiner HE, et al. Warfarin Pharmacogenomics in Diverse Populations. Pharmacotherapy. 2017. PMID: 28672100. doi:10.1002/phar.1982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。